作者
Carlos KH Wong, David TW Lui, Angel YC Lui, Ashley CY Kwok, Marshall CH Low, Kristy TK Lau, Ivan CH Au, Xi Xiong, Matthew SH Chung, Eric HY Lau, Benjamin J Cowling
发表日期
2022/1/1
期刊
Diabetes & Metabolism
卷号
48
期号
1
页码范围
101307
出版商
Elsevier Masson
简介
Background and objectives
Type 2 diabetes mellitus (T2DM) patients with Coronavirus Disease 2019 (COVID-19) have poorer prognosis. Inconclusive evidence suggested dipeptidyl peptidase-4 inhibitors (DPP4i) might reduce inflammation and prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry, hence further evaluation on DPP4i is needed.
Methods
1214 Patients with T2DM were admitted with COVID-19 between 21st January 2020 and 31st January 2021 in Hong Kong. Exposure was DPP4i use within the 90 days prior to admission for COVID-19. Assessed outcomes included clinical deterioration, clinical improvement, low viral load, positive Immunoglobulin G (IgG) antibody, hyperinflammatory syndrome, proportion of IgG antibody, clinical status and length of hospitalization. Multivariable logistic and linear regression models were performed to estimate odds ratios (OR) and their 95 …
学术搜索中的文章
CKH Wong, DTW Lui, AYC Lui, ACY Kwok, MCH Low… - Diabetes & Metabolism, 2022